Hoth Therapeutics (HOTH) has been granted a patent for the HT-KIT platform by the Japan Patent Office on May 7, with exclusive protection until August 27, 2039. The granted patent protects Hoth’s approach of using splice-switching oligonucleotides to selectively disrupt KIT gene expression in mast cells-cells implicated in conditions ranging from chronic hives to rare cancers. HT-KIT is one of several novel platforms under development at Hoth Therapeutics.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics announces Expanded Access Program aplication for HT-001
- Hoth Therapeutics Prepares Presentation on Clinical Programs
- Hoth Therapeutics Faces Nasdaq Compliance Challenge
- Hoth Therapeutics reports preclinical data for HT-KIT
- Hoth Therapeutics granted Japanese patent for novel RNA-based cancer therapy